Last reviewed · How we verify
Immediate-release omeprazole
Omeprazole irreversibly inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.
Omeprazole irreversibly inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.
At a glance
| Generic name | Immediate-release omeprazole |
|---|---|
| Sponsor | University of Louisville |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Omeprazole is a proton pump inhibitor (PPI) that binds to and inactivates the H+/K+-ATPase enzyme on the secretory surface of gastric parietal cells. This blocks the final step of gastric acid production, significantly reducing intragastric acidity. The immediate-release formulation allows rapid onset of acid suppression compared to delayed-release formulations.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Zollinger-Ellison syndrome
- Prevention of NSAID-induced ulcers
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Vomiting
- Hypomagnesemia (with long-term use)
- Vitamin B12 deficiency (with long-term use)
Key clinical trials
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participant (PHASE1)
- A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants (PHASE1)
- Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors (PHASE1)
- LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients (PHASE1)
- GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects (PHASE1)
- Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill (PHASE3)
- Drug-drug Interaction Study to Evaluate the Effect of Omeprazole on CG5503 (Tapentadol) (PHASE1)
- A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Immediate-release omeprazole CI brief — competitive landscape report
- Immediate-release omeprazole updates RSS · CI watch RSS
- University of Louisville portfolio CI